It seems that in HER-2 positive breast cancer cells, at least in vitro, HRG stimulates the formation of certain HER-3- and HER-4-based heterodimers, thus generating new data regarding the way we could therapeutically target them. The gene discussed is ERBB3; the disease is breast carcinoma.